Literature DB >> 8332152

A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease.

J A Wilimas1, P M Flynn, S Harris, S W Day, R Smith, P J Chesney, J H Rodman, J M Eguiguren, D L Fairclough, W C Wang.   

Abstract

BACKGROUND: Because of their susceptibility to pneumococcal sepsis, children with sickle cell disease and fever are usually hospitalized for antibiotic therapy. Outpatient treatment may be a safe and less expensive alternative for selected patients.
METHODS: After evaluation in the emergency room, children ranging from 6 months to 12 years of age who had sickle hemoglobinopathies and temperatures exceeding 38.5 degrees C were randomly assigned to treatment as either inpatients or outpatients. We excluded from randomization children at higher risk of sepsis (as defined by specific criteria, including temperature above 40 degrees C, white-cell count below 5000 per cubic millimeter or above 30,000 per cubic millimeter, and the presence of pulmonary infiltrates) or with complications of sickle cell disease (such as a hemoglobin level below 5 g per deciliter, dehydration, or severe pain); these children were treated as inpatients. All patients received an initial intravenous dose of ceftriaxone (50 mg per kilogram of body weight). Those treated as outpatients returned 24 hours later for a second dose of ceftriaxone, whereas the in patients were treated as directed by their physicians.
RESULTS: None of the 86 patients (with a total of 98 febrile episodes) in the randomized groups had sepsis, as compared with 6 of the 70 patients (7 of 86 episodes) excluded because of higher risk (P = 0.004). Among the 44 children (50 episodes) assigned to outpatient treatment, there were 11 hospitalizations (22 percent of episodes) within two weeks after treatment (95 percent confidence interval, 12 to 36 percent), whereas after inpatient care only a single patient (2 percent of episodes) was rehospitalized. When the randomized groups were compared, outpatient treatment saved a mean of $1,195 per febrile episode. The median hospital stay was 3 days (range, 1 to 6) for the children randomly assigned to inpatient care and 4 days (range, 1 to 18) for the higher-risk children treated as inpatients (P < 0.001).
CONCLUSIONS: With the use of conservative eligibility criteria, at least half the febrile episodes in children with sickle cell disease can be treated safely on an outpatient basis, with substantial reductions in cost.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8332152     DOI: 10.1056/NEJM199308123290705

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

1.  Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks?

Authors:  D N Williams
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

2.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 3.  Aetiology and management of children with acute fever of unknown origin.

Authors:  G O Akpede; G I Akenzua
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Prevention and management of infection in children with sickle cell anaemia.

Authors:  W Y Wong
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Improving outcomes in children with sickle cell disease: treatment considerations and strategies.

Authors:  Ali Amid; Isaac Odame
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

7.  Chart Card: feasibility of a tool for improving emergency department care in sickle cell disease.

Authors:  Lynne Neumayr; Steven Pringle; Stephen Giles; Keith C Quirolo; Susan Paulukonis; Elliott P Vichinsky; Marsha J Treadwell
Journal:  J Natl Med Assoc       Date:  2010-11       Impact factor: 1.798

8.  Outcomes of febrile events in pediatric patients with sickle cell anemia.

Authors:  Krishnaveni Sirigaddi; Inmaculada Aban; Amelia Jantz; Brandi M Pernell; Lee M Hilliard; Smita Bhatia; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

Review 9.  Salmonella epidural abscess in sickle cell disease: failure of the nonsurgical treatment.

Authors:  Patrick Diebold; James Humbert; Vincent de Paul Djientcheu; François Gudinchet; Benedict Rilliet
Journal:  J Natl Med Assoc       Date:  2003-11       Impact factor: 1.798

Review 10.  Sickle cell disease in childhood: from newborn screening through transition to adult medical care.

Authors:  Charles T Quinn
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.